The Source of Truth for Market Authorization Holders (MAH) and Immunizing Agents and their abbreviations have been updated. Please refer to the Immunization page for the details.
The Out of country products and Special access programs guidelines has been updated. Please refer to the Immunization page for the details.
Stakeholders of the Public Health Community have requested to create terminology concepts for the WHO-authorized vaccines administered outside of Canada. This is to support use cases related to international travel back to/into Canada (e.g. snowbirds, newcomers, etc.). This will help with immunization surveillance and will allow to have a more comprehensive understanding of vaccination coverage rates in Canada.
Special Access Products (SAPs) and international vaccines cannot be found on DPD. There are no MAH for these products as they are not licensed in Canada. The new pattern will be as follows:
Pattern:
FSN: Trade Name (qualifier) Strength Dose Form (real clinical drug)
English PT: PHAC Product Abbreviation Trade Name (qualifier) (strength)
The below sections are currently under review due to the Immunization RedesignIf you have questions or need information, please contact us |
---|
This content is designed for use when populating a record at the point of administration and includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the client. It consists of concepts from the Proprietary Medicinal Product class and from the SNOMED CT Pharmaceutical / biologic product hierarchy, that are described using their trade name (brand name).
The scope of this subset is passive immunizing agents that are currently licensed for use in Canada and those obtained through special access programs. The subset includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the client. Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent. This content is intended to be used when populating a record at the point of administration.
The format for the Fully Specified Name (FSN) is as follows:
Trade name (qualifier) Strength Dose Form Manufacturer or Marketing Authorization Holder (MAH) (product)
E.g.: HepaGam B 312 international units per milliliter liquid for injection Cangene Corporation (product)
The format for the Preferred Synonym (PS) is as follows:
PHAC/CHI Product Abbreviation Trade name (qualifier)(strength) PHAC/CHI Manufacturer or Marketing Authorization Holder (MAH) Abbreviation
e.g.: HBIg HepaGam B Cang